SeaStar Medical's QUELIMMUNE Shows Promise in Treating Pediatric AKI
SeaStar Medical's QUELIMMUNE device, approved by the FDA, significantly reduces mortality rates in pediatric patients with acute kidney injury (AKI) by targeting the cytokine storm at its source.
Dr. Kevin Chung, Chief Medical Officer at SeaStar Medical Holding Corporation, and Dr. Stuart L. Goldstein from Cincinnati Children's Hospital Medical Center, discussed the promising results of QUELIMMUNE, a humanitarian medical device approved by the U.S. FDA for treating pediatric acute kidney injury (AKI) due to sepsis or septic conditions. Pediatric AKI, a sudden episode of kidney failure, can lead to severe complications including chronic kidney disease or end-stage renal disease, with a high mortality rate of 50% among the approximately 4,000 cases reported annually in the U.S.
QUELIMMUNE, granted approval under a Humanitarian Device Exemption (HDE) by the FDA in February 2024, targets the dysregulated innate immune response in severely ill patients, specifically the cytokine storm, leading to a significant reduction in mortality rates from 50% to 25%. Dr. Goldstein highlighted the device's effectiveness in trials, noting dramatic improvements in patients within 24 to 48 hours and a remarkable decrease in the need for chronic dialysis among survivors.
Beyond pediatric AKI, SeaStar Medical is exploring QUELIMMUNE's potential in treating adult AKI and other conditions where the innate immune system is disturbed, supported by six Breakthrough Device Designations from the FDA. This innovative approach represents a significant advancement in treating life-threatening conditions with limited treatment options.